Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers develop infected tissue model for Aganocide compounds

Two common and important human pathogens, P. aeruginosa and S. aureus, are implicated in many clinical diseases of the eye and skin, including keratitis and impetigo, respectively. Infections with their associated toxins can result in the destruction of underlying tissue.

16 Sep 2010

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, today presented five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

16 Sep 2010

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today participated in the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy

16 Sep 2010

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens.

16 Sep 2010

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

16 Sep 2010

Researchers find NCT analogs show antimicrobial, anticoagulant activity

Catheter-related bacteremia can be a significant cause of sickness and death for hemodialysis patients. The anticoagulant heparin is commonly used as a catheter lock solution to prevent thrombosis; however has limited antimicrobial activity.

16 Sep 2010

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

ViroPharma Incorporated today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections, a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.

16 Sep 2010

ASG-5ME compound kills pancreatic cancer cells: Researchers

A new investigational drug designed to penetrate and attack pancreatic cancer cells has been administered to a patient for the first time ever at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

16 Sep 2010

ESMO honors three eminent cancer specialists for their contribution towards medical research

The European Society for Medical Oncology (ESMO) honors three eminent cancer specialists for their contribution to the advancement of medical research. The awards will be presented to Hilary Calvert, Alberto Costa and Bengt Glimelius at the 35th ESMO Congress, to take place from 8-12 October in Milan, Italy.

16 Sep 2010

Novel Compound's NVC-422 broad-spectrum antimicrobial agent kills P. mirabilis bacteria in catheters

Patients fitted with long-term bladder catheters often face a potentially serious complication caused by a Gram-negative bacteria Proteus mirabilis that can colonize the catheters.

16 Sep 2010

Researchers investigate antimicrobial activity of Aganocide compounds against H1N1

Fears over the influenza A virus (H1N1; sometimes referred to as swine flu) have motivated researchers to investigate the antimicrobial activity of the Aganocide compounds against viruses. In a study presented at this year's Interscience Conference on Antimicrobial Agents and Chemotherapy, a team led by Professor Markus Nagl, MD of Medical University of Innsbruck and including D. Debabov, PhD and K. Hybiske, PhD of NovaBay Pharmaceuticals evaluated the in vitro virucidal activity of three compounds: N-chlorotaurine, a compound produced by human phagocytes; and two NCT analogs, NVC-612 and NVC-422.

16 Sep 2010

New sperm freezing technique may be a boon for IVF

A new improved method of freezing and storing sperm for future use in infertility treatment has arrived as a boon for couples wanting babies.

16 Sep 2010

NPS Pharmaceuticals intends to offer public offering of common stock

NPS Pharmaceuticals, Inc. today announced that it intends to offer and sell approximately $41,290,000 of its common stock in an underwritten public offering.

16 Sep 2010

Access Pharmaceuticals launches product website for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.

15 Sep 2010

ESMO honors eminent cancer specialists

15 Sep 2010

Flora Skeates represents Cancer Research UK in photographic exhibition at Oxo Tower

Mum-of-two Flora Skeates says she owes her life to cancer research after surviving bowel cancer twice within two years. That is why she is representing Cancer Research UK in a stunning new photographic exhibition to encourage people to remember the charity in their Will.

15 Sep 2010

Stanford Cancer Center to use TrueBeam radiation therapy technology for cancer patients

On Thursday, Sept. 16, the Stanford Cancer Center will become the first treatment center on the West Coast and the fifth in the world to offer cancer patients the TrueBeam, a machine that represents an exponential leap forward in the speed, power and precision of radiation therapy.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

Optimer Pharmaceuticals, Inc. announced the presentation of new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

15 Sep 2010

RAB-1 monoclonal antibody study shows positive result for rabies

With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

15 Sep 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers develop infected tissue model for Aganocide compounds

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Researchers find NCT analogs show antimicrobial, anticoagulant activity

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

ASG-5ME compound kills pancreatic cancer cells: Researchers

ESMO honors three eminent cancer specialists for their contribution towards medical research

Novel Compound's NVC-422 broad-spectrum antimicrobial agent kills P. mirabilis bacteria in catheters

Researchers investigate antimicrobial activity of Aganocide compounds against H1N1

New sperm freezing technique may be a boon for IVF

NPS Pharmaceuticals intends to offer public offering of common stock

Access Pharmaceuticals launches product website for MuGard

ESMO honors eminent cancer specialists

Flora Skeates represents Cancer Research UK in photographic exhibition at Oxo Tower

Stanford Cancer Center to use TrueBeam radiation therapy technology for cancer patients

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

RAB-1 monoclonal antibody study shows positive result for rabies

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in